Essential Thrombocythemia

Common Name(s)

Essential Thrombocythemia

Essential thrombocythemia belongs to a group of conditions called myeloproliferative disorders. Myeloproliferative disorders cause platelets, white blood cells and red blood cells to grow abnormally in the bone marrow (the soft tissue inside the hollow part of bones that helps form blood cells). In essential thrombocythemia, the body produces too many platelet cells. The signs and symptoms vary from person to person, with up to two-thirds of patients not having any symptoms when the platelet cell count first increases. Signs and symptoms may include significant increased production of megakaryocyte (a cell in the bone marrow that is responsible for making platelets), enlargement of the spleen (splenomegaly), and bleeding and/or clotting episodes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Essential Thrombocythemia" returned 349 free, full-text research articles on human participants. First 3 results:

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
 

Author(s): Srdan Verstovsek, Stephane Courby, Martin Griesshammer, Ruben A Mesa, Carrie Baker Brachmann, Jun Kawashima, Julia D Maltzman, Lixin Shao, Yan Xin, Daniel Huang, Ashish Bajel

Journal: Leuk. Res.. 2017 Sep;60():11-17.

 

Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis. This phase 2, open-label, randomized study evaluated the efficacy and safety of oral once-daily momelotinib (100mg and 200mg) for the treatment of polycythemia ...

Last Updated: 16 Jun 2017

Go To URL
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
 

Author(s): Yoko Kubuki, Kotaro Shide, Takuro Kameda, Takumi Yamaji, Masaaki Sekine, Ayako Kamiunten, Keiichi Akizuki, Haruko Shimoda, Yuki Tahira, Kenichi Nakamura, Hiroo Abe, Tadashi Miike, Hisayoshi Iwakiri, Yoshihiro Tahara, Mitsue Sueta, Kanna Hashimoto, Shojiro Yamamoto, Satoru Hasuike, Tomonori Hidaka, Kenji Nagata, Akira Kitanaka, Kazuya Shimoda

Journal: Ann Lab Med. 2017 Mar;37(2):159-161.

 

Last Updated: 28 Dec 2016

Go To URL
Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.
 

Author(s): Luana Magalhães Navarro, Damila Cristina Trufelli, Debora Rodrigues Bonito, Auro Del Giglio, Patricia Weinschenker Bollmann

Journal: Rev Assoc Med Bras (1992). 2016 Oct;62(7):647-651.

 

In patients with essential thrombocythemia (ET), the vascular complications contribute to morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET-thrombosis) has recently been ...

Last Updated: 7 Dec 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Essential Thrombocythemia" returned 15 free, full-text review articles on human participants. First 3 results:

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
 

Author(s): Gunnar Birgegård

Journal: Curr Hematol Malig Rep. 2016 Oct;11(5):348-55.

 

Anagrelide (ANA) is a drug with specific platelet-lowering activity, used primarily in ET, registered as a second-line drug in essential thrombocythemia (ET) in Europe and in some countries as first-line therapy, in USA licensed by FDA for thrombocythemia in myeloproliferative neoplasms ...

Last Updated: 22 Sep 2016

Go To URL
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
 

Author(s): T Barbui, J Thiele, A M Vannucchi, A Tefferi

Journal:

 

The 2001/2008 World Health Organization (WHO)-based diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) were recently revised to accomodate new information on disease-specific mutations and underscore distinguishing morphologic ...

Last Updated: 2 Feb 2016

Go To URL
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
 

Author(s): S Cerquozzi, A Tefferi

Journal:

 

Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-ABL1-negative myeloproliferative neoplasms and are characterized by relatively long median survivals (approximately 14 and 20 years, respectively). Potentially fatal disease complications in ...

Last Updated: 14 Nov 2015

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
 

Status: Recruiting

Condition Summary: Essential Thrombocythemia

 

Last Updated: 24 Jul 2017

Go to URL
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
 

Status: Recruiting

Condition Summary: MPN; Essential Thrombocythemia

 

Last Updated: 24 Jul 2017

Go to URL